Tikun Olam was established in 2006 and acquired by Cannbit Pharmaceuticals in 2019. Tikun Olam-Cannbit is Israel’s first and leading supplier of cannabis. A groundbreaker in clinical research, it is renowned worldwide as a pioneer in the field of modern medical cannabis. Since its establishment, Tikun Olam-Cannbit has treated more than 30,000 patients in Israel from childhood through to old age with a variety of illnesses, and has the most experience worldwide in the treatment of patients and in alleviating their suffering through medical cannabis. The company has 13 years of experience in clinical research and more than 35 clinical and pre-clinical research studies which have been published in the world’s foremost scientific journals.
Tikun Olam-Cannbit operates throughout the value chain of the medical cannabis world, while maintaining an ecosystem that integrates values of sustainability, therapeutic continuity, and uniformity in the quality of its products. Patients are at the core of the company’s thinking, planning and action, and a unique envelope has been built for years around them. The Tikun Olam-Cannbit patients receive products according to the treatment continuity he or she needs, and we keep for each patient his or her precisely-tailored strain, with the same percentages of active ingredients that make the treatment the most effective, the most stable, and the best for each individual. Tikun Olam-Cannbit’s ecosystem includes a research and clinical trials system, genetic R&D for development of unique strains, Israeli agriculture – cultivation and propagation farms, a production facility, an advanced laboratory and technological R&D, a logistics center, a dispensary and direct delivery to the customer’s home, as well as a service and pharma system that includes patient training and counseling, while maintaining a personalized treatment sequence.